EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

Catharine I Paules iD, Jing Wang, Kay M Tomashek iD, Tyler Bonnett iD, Kanal Singh iD, Vincent C Marconi iD, Richard T Davey iD, David C Lye iD, Lori E Dodd, Otto O Yang iD, Constance A Benson iD, Gregory A Deye iD und 9 weitere

Annals of Internal Medicine · 2024

DOI: 10.7326/m23-2593 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Catharine I Paules und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania (C.I.P.). Hauptthemen laut MEDLINE: Azetidines, COVID-19, Purines, Pyrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesCOVID-19PurinesPyrazolesSulfonamidesAdultHumansAntiviral AgentsCOVID-19 Drug TreatmentImmunologic FactorsSARS-CoV-2Treatment OutcomeDouble-Blind Method

Substanzen

Antiviral AgentsAzetidinesbaricitinibImmunologic FactorsPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania (C.I.P.).
  • Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland (J.W., T.B.).
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).
  • Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia (V.C.M.).
  • National Centre for Infectious Diseases, Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, and Lee Kong Chian School of Medicine, Singapore (D.C.L.).
  • Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California (O.O.Y.).

ORCID-Profile: Catharine I Paules, Kay M Tomashek, Tyler Bonnett, Kanal Singh, Vincent C Marconi, Richard T Davey, David C Lye, Otto O Yang, Constance A Benson, Gregory A Deye, Sarah B Doernberg, Noreen A Hynes, Robert Grossberg, Cameron R Wolfe, William R Short, Gail E Potter

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Paules, C. I., Wang, J., Tomashek, K. M., Bonnett, T., Singh, K., Marconi, V. C., Davey, R. T., Lye, D. C., Dodd, L. E., Yang, O. O., Benson, C. A., Deye, G. A., Doernberg, S. B., Hynes, N. A., Grossberg, R., Wolfe, C. R., Nayak, S. U., Short, W. R., Voell, J., …, & Rapaka, R. R. (2024). A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Annals of Internal Medicine. https://doi.org/10.7326/m23-2593

Vancouver

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, et al. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Annals of Internal Medicine. 2024. doi:10.7326/m23-2593

BibTeX
@article{Paules2024,
  author = {Paules, Catharine I and Wang, Jing and Tomashek, Kay M and Bonnett, Tyler and Singh, Kanal and Marconi, Vincent C and Davey, Richard T and Lye, David C and Dodd, Lori E and Yang, Otto O and Benson, Constance A and Deye, Gregory A and Doernberg, Sarah B and Hynes, Noreen A and Grossberg, Robert and Wolfe, Cameron R and Nayak, Seema U and Short, William R and Voell, Jocelyn and Potter, Gail E and Rapaka, Rekha R},
  title = {A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2},
  journal = {Annals of Internal Medicine},
  year = {2024},
  doi = {10.7326/m23-2593}
}
Kostenlos starten →